Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
BLIS Technologies Limited, together with its subsidiaries, specializes in creating and distributing health-focused products. These offerings are underpinned by unique bacterial strains that exhibit bacteriocin activity. The company prominently features several key probiotic strains: BLIS K12, a supplement engineered to bolster ear, nose, and throat well-being in young children, in addition to enhancing immune function and combating halitosis; BLIS M18, an oral probiotic designed to promote robust dental and gum health; and BLIS Q24, a probiotic formulation aimed at harmonizing and rejuvenating the skin's microbiome, thereby fostering healthier, clearer, and more radiant skin. Established in 2000, BLIS Technologies is based in Dunedin, New Zealand, and maintains a global presence with operations spanning New Zealand, the Asia Pacific region, Europe, the Middle East, Africa, and North America.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu